van Mil Group

Positions available

Within the FXR-IBD consortium, we have currently 2 positions for post-doctoral researchers.

FXR-IBD is a FP7 Marie Curie Industry-Academia Partnerships and Pathways (IAPP) network of 1 academic partner (UMC Utrecht) and 2 industrial partners (TES Pharma and Enterome Bioscience) dedicated to research and development of novel diagnostic and therapeutic approaches for inflammatory bowel disease (IBD).
Inflammatory Bowel Disease (IBD) covers a group of disorders that are all characterized by chronic intestinal inflammation. Complications can be severe and in rare cases, IBD might even lead to mortality. IBD appears to result from a deregulated mucosal immune system combined with a compromised intestinal epithelial barrier function in genetically predisposed individuals.
Current treatment options of patients with IBD are mainly aimed at suppressing the immune response. However, although reasonably effective, treatment failures and significant side effects often occur. This clearly stresses the need for novel treatment options in the treatment of IBD.
Another problem is that no specific, non-invasive test exists to monitor IBD disease activity. Currently, patients have to undergo endoscopy, which is a burden for the patient, but may also present complications.
In this study we aim to:
1. Develop a novel treatment for IBD, using the recently described anti-inflammatory effects of the bile acid sensor farnesoid X receptor (FXR). We aim to develop agonists capable of selectively activating the FXR as a pharmaceutical lead.
2. Develop a non-invasive diagnostic tool using well-defined changes in the gut microbiome of people affected with IBD as a marker to diagnose and monitor disease progression or remission in stool samples.

Vacancy 1:
The University Medical Center Utrecht, the Netherlands, offers a 2-year post-doctoral position.
The fellow will gain detailed insights in the mechanisms by which FXR inhibits inflammation in the intestine using ChIP-sequencing and expression analyses.
In addition, the fellow will aim to unravel the events upstream of FXR activation using SILAC/RIME and mass spectrometry to determine post-translational modifications (PTM) and FXR-interacting proteins. Together, these experiments will eminently lead to more insights in the different FXR upstream and downstream signaling pathways specifically contributing to its anti-inflammatory activity and will enable rational design of selective FXR ligands.

Vacancy 2:
Enterome Bioscience, Paris, France, offers a 1-year post-doctoral position. The fellow will develop a microbiome fingerprint using whole genome metagenomics profiling on stool samples of IBD patients. This fingerprint will be translated into a non-invasive diagnostic tool.

More information on the FXR-IBD project and the application procedure can be found at

PhD students and Postdocs interested in joining the lab, please contact Saskia van Mil (s.w.c.vanmil at / +31 88 7550005)